Message #75 From:
NewsBot Date: December 12, 2006 01:01:00 PM
ALNY News Alnylam Announces Proceeds of Common Stock Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the
net proceeds to the company from its offering of 4,700,000 shares of
common stock will be approximately $101 million. The offering is
underwritten by Banc of America Securities LLC. The company expects the
closing of the offering to occur on December 15, 2006.
Alnylam is a leading biopharmaceutical company developing novel
therapeutics based on RNA interference, or RNAi.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the company’s
common stock, nor shall there be any sale of the common stock in any
state in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
state.
Various statements in this release concerning our future expectations,
plans and prospects, including the estimated net proceeds from the
offering and the expected closing date for the offering, constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including risks related to fluctuations in our stock price, as well as
those risks more fully discussed in the “Certain
Factors That May Affect Future Results”
section of our most recent Quarterly Report on Form 10-Q on file with
the Securities and Exchange Commission. In addition, any forward-looking
statements represent our views only as of today and should not be relied
upon as representing our views as of any subsequent date. We do not
assume any obligation to update any forward-looking statements.
